Last updated: February 19, 2026
This report identifies key suppliers for three active pharmaceutical ingredients (APIs): brompheniramine maleate, dextromethorphan hydrobromide, and pseudoephedrine hydrochloride. It details their reported manufacturing capabilities, regulatory compliance status, and relevant market presence, providing data for supply chain diligence and strategic sourcing.
Who are the primary manufacturers and suppliers of brompheniramine maleate?
Brompheniramine maleate, an antihistamine, is manufactured by multiple global chemical and pharmaceutical companies. Supply is concentrated among entities with established expertise in API synthesis and stringent quality control processes.
Key Manufacturers and Suppliers:
- BASF SE: A major chemical producer with a pharmaceutical division. BASF reports capabilities in producing a broad range of APIs, including those for cough and cold formulations. Their global manufacturing footprint and adherence to Good Manufacturing Practices (GMP) are critical.
- Granules India Limited: An India-based pharmaceutical company specializing in APIs and finished dosage forms. Granules India lists brompheniramine maleate among its product offerings, emphasizing its backward integration and GMP-certified facilities.
- Anacor Pharmaceuticals (acquired by Pfizer): While Anacor focused on other therapeutic areas, its manufacturing assets and supply chains may have been integrated into Pfizer’s broader API production network. Pfizer is a significant player in global API manufacturing.
- Other Regional Manufacturers: Numerous smaller and mid-sized API manufacturers in India, China, and select European countries also produce brompheniramine maleate. These suppliers often cater to regional markets and may offer more competitive pricing. Due diligence on their regulatory certifications and audit history is essential.
Production Capacities:
Specific production volumes are proprietary, but industry estimates suggest a global annual production capacity for brompheniramine maleate in the range of hundreds of metric tons. This capacity is sufficient to meet current global demand.
Regulatory Compliance:
Suppliers typically aim for compliance with relevant pharmacopoeial standards, including USP (United States Pharmacopeia) and EP (European Pharmacopoeia). Many also hold Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) or have their facilities inspected and approved by regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Market Trends:
The market for brompheniramine maleate is mature. Growth is primarily driven by its inclusion in combination products for cold and allergy relief. Supply chain disruptions can impact availability, as evidenced by past shortages attributed to manufacturing issues or raw material availability.
What are the leading sources for dextromethorphan hydrobromide?
Dextromethorphan hydrobromide, a cough suppressant, is a high-volume API with a well-established global supply chain. Production is dominated by a few key international players, with significant manufacturing bases in Asia.
Key Manufacturers and Suppliers:
- Mallinckrodt Pharmaceuticals: A significant producer of APIs, including dextromethorphan hydrobromide. Mallinckrodt has a long history of API manufacturing and operates multiple GMP-compliant facilities.
- Shandong Xinhua Pharmaceutical Co., Ltd.: A major Chinese pharmaceutical manufacturer that is a substantial global supplier of dextromethorphan hydrobromide. Xinhua adheres to international GMP standards and supplies to regulated markets.
- DSM (Royal DSM N.V.): While DSM’s primary focus has shifted in recent years, historically they have been involved in the production of various pharmaceutical intermediates and APIs, potentially including dextromethorphan or its precursors.
- DepoMed, Inc. (acquired by Acorda Therapeutics): Acquisitions can lead to shifts in supply chains. DepoMed’s API production capabilities, if they included dextromethorphan, would now fall under Acorda Therapeutics' or subsequent entities.
- Anhui Fengyuan Pharmaceutical Co., Ltd.: Another Chinese manufacturer identified as a supplier of dextromethorphan hydrobromide, emphasizing GMP compliance and export capabilities.
Production Capacities:
Global production capacity for dextromethorphan hydrobromide is estimated to be several thousand metric tons annually, reflecting its widespread use. China and India are key manufacturing hubs contributing significantly to this capacity.
Regulatory Compliance:
Suppliers typically comply with USP, EP, and JP (Japanese Pharmacopoeia) standards. FDA and EMA inspections are common for suppliers targeting regulated markets. The synthesis of dextromethorphan is complex, requiring controlled processes to ensure purity and potency.
Market Trends:
Demand for dextromethorphan hydrobromide is stable, driven by its efficacy and safety profile as a non-opioid cough suppressant. Price competition is a significant factor in this market. Supply security is also a consideration, given the potential for regulatory scrutiny on manufacturing processes.
Which companies are prominent suppliers of pseudoephedrine hydrochloride?
Pseudoephedrine hydrochloride, a decongestant, is a strategically important API due to its dual use as a precursor in the illicit synthesis of methamphetamine. This has led to significant regulatory oversight and a more concentrated supplier landscape focused on compliance.
Key Manufacturers and Suppliers:
- Perrigo Company plc: A significant supplier of OTC pharmaceuticals and APIs. Perrigo has been a key source for pseudoephedrine hydrochloride, operating under strict regulatory controls.
- Jubilant Life Sciences Limited: An integrated global pharmaceutical and life sciences company based in India. Jubilant is a reported manufacturer of pseudoephedrine hydrochloride, emphasizing its compliance with global regulatory standards and its capacity for large-scale production.
- Sanofi S.A.: A multinational pharmaceutical company. While Sanofi’s primary focus is on branded and generic finished products, their integrated supply chain often includes API manufacturing or strategic sourcing partnerships for key APIs like pseudoephedrine hydrochloride.
- Endo International plc: Another pharmaceutical company that has been involved in the supply of pseudoephedrine hydrochloride. Regulatory and market dynamics can influence their ongoing direct manufacturing or sourcing roles.
Production Capacities:
Global production capacity is carefully managed due to regulatory constraints. Exact figures are not publicly disclosed but are controlled to prevent diversion. Production is typically concentrated in countries with robust regulatory frameworks for controlled substances.
Regulatory Compliance:
Suppliers must comply with stringent national and international regulations regarding controlled substances, including the U.S. Controlled Substances Act and equivalent international agreements. This includes rigorous tracking, security, and reporting requirements. Facilities are subject to frequent audits by drug enforcement agencies. Pharmacopoeial standards (USP, EP) are also critical.
Market Trends:
The market for pseudoephedrine hydrochloride is heavily influenced by regulations designed to combat its diversion for illicit use. These regulations include sales restrictions (e.g., behind-the-counter sales) and limits on purchase quantities. This has led to the development of alternative decongestants (e.g., phenylephrine), though pseudoephedrine remains preferred by many for its efficacy. Supply is stable but subject to regulatory policy shifts. Manufacturers are required to implement robust Know Your Customer (KYC) and Know Your Manufacturer (KYM) programs.
Key Takeaways
- Brompheniramine Maleate: A mature market with global suppliers like BASF and Granules India. Supply chain resilience depends on GMP compliance and stable raw material sourcing.
- Dextromethorphan Hydrobromide: Dominated by large manufacturers, particularly from China (e.g., Shandong Xinhua), with Mallinckrodt also a key player. Production capacity is robust.
- Pseudoephedrine Hydrochloride: Highly regulated due to diversion risks, leading to fewer, more scrutinized suppliers like Perrigo and Jubilant Life Sciences. Regulatory compliance is paramount.
- Geographic Concentration: While global, significant manufacturing capacity for these APIs resides in India and China, alongside established Western pharmaceutical companies.
- Quality and Compliance: Adherence to USP, EP, and GMP standards, along with successful FDA/EMA inspections, is a baseline requirement for all credible suppliers.
Frequently Asked Questions
-
What is the primary risk associated with sourcing pseudoephedrine hydrochloride?
The primary risk is diversion for illicit methamphetamine production, leading to stringent regulatory controls, potential supply disruptions, and increased compliance burdens.
-
Are there any significant patent cliffs or generic competition issues for these APIs?
As these APIs are largely off-patent, the market is characterized by generic competition. The focus for suppliers is on efficient, compliant manufacturing and supply chain reliability rather than novel patent protection for the API itself.
-
What is the typical lead time for API orders from these suppliers?
Lead times can vary significantly based on order volume, supplier inventory, production schedules, and shipping logistics, but typically range from 4 to 16 weeks for bulk API orders.
-
How do suppliers ensure the quality and purity of their APIs?
Suppliers adhere to stringent Good Manufacturing Practices (GMP), conduct in-process controls, perform final product testing against pharmacopoeial monographs, and often undergo regular audits by regulatory agencies and customers.
-
What regulatory hurdles must be overcome when importing these APIs into the United States?
Importation requires compliance with FDA regulations, including site registration, drug master file (DMF) submissions or equivalent, and adherence to current GMP. For pseudoephedrine hydrochloride, additional DEA regulations for listed chemicals apply.
Citations
[1] Bloomberg Terminal Database. (n.d.). Pharmaceutical API Market Intelligence.
[2] U.S. Food and Drug Administration. (n.d.). Drugs@FDA. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
[3] European Medicines Agency. (n.d.). EudraGMDP Database. Retrieved from https://www.ema.europa.eu/en/medicines/human/compliance/eudragmp-database
[4] United States Pharmacopeia. (n.d.). USP-NF Online. Retrieved from https://online.uspnf.com/
[5] Granules India Limited. (n.d.). Product Portfolio. Retrieved from https://www.granulesindia.com/
[6] Shandong Xinhua Pharmaceutical Co., Ltd. (n.d.). Product Catalog. Retrieved from [https://www. XinhuaPharma.com/](https://www. XinhuaPharma.com/)
[7] Jubilant Life Sciences Limited. (n.d.). API Offerings. Retrieved from https://www.jubilantlifesciences.com/
[8] Perrigo Company plc. (n.d.). API Manufacturing. Retrieved from https://www.perrigo.com/
[9] Drug Enforcement Administration. (n.d.). Controlled Substances Act. Retrieved from https://www.dea.gov/
